Collegium Pharmaceutical nominates Michael Donovan; director John Fallon to retire
Collegium Pharmaceutical's board approved Michael Donovan, a former Ernst & Young audit partner, as a director nominee for the 2026 annual meeting. Director John Fallon, M.D., who has served since 2016, said he will not stand for re-election and will retire from the board at that meeting, which the company says reflects board refreshment and succession planning rather than any disagreement.
Key points
- Board approved Michael Donovan's nomination on April 6, 2026, for election at the 2026 Annual Meeting of Shareholders
- Donovan, 60, was an EY audit partner from 2002 and Office Managing Partner of EY's Kendall Square biotechnology office from 2014 to 2024
- Dr. John Fallon advised the board on April 2, 2026, that he will retire at the annual meeting after serving as a director since 2016
- The company says Fallon's departure is not the result of any disagreement with the company
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 6:59 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 07, 2026.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.